Aug 08, 2022 / 04:00PM GMT
Operator
My name is Jason, and I will be your conference facilitator today for Amgen's conference call from the 2022 World Conference on Lung Cancer. (Operator Instructions).
I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.
David M. Reese - Amgen Inc. - EVP of Research & Development
Actually, Jason, this is David Reese, Head of Research and Development at Amgen. I'll be helping to host today's conference. We'll provide an oncology clinical update on some of our lung cancer programs, based on data that were presented here in Vienna at the World Conference on Lung Cancer over the last couple of days. We know there's a lot of interest in these data, and so we'll move into data summaries very quickly here.
Can we advance the slide, please? Here is our safe harbor statement and today's agenda. After very short remarks from me, Dr. Bob Li will present an update on the LUMAKRAS combination studies presented here, including both checkpoint inhibitor combinations as well as the SHP2 combination
Amgen Inc Conference Call from 2022 World Conference on Lung Cancer (WCLC) Transcript
Aug 08, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers